Krystal Biotech (NASDAQ:KRYS) Stock Rating Reaffirmed as Buy by HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 10.85% from the company’s current price.

KRYS has been the subject of several other research reports. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. The Goldman Sachs Group initiated coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price for the company. Citigroup raised their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $377.20.

Krystal Biotech Stock Up 1.7%

NASDAQ KRYS traded up $5.41 during trading hours on Thursday, hitting $325.66. The company’s stock had a trading volume of 82,085 shares, compared to its average volume of 326,179. The stock has a fifty day moving average of $340.18 and a 200 day moving average of $324.12. Krystal Biotech has a twelve month low of $183.03 and a twelve month high of $382.54. The firm has a market capitalization of $9.64 billion, a P/E ratio of 40.73 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, analysts predict that Krystal Biotech will post 7.40 earnings per share for the current year.

Insider Activity

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently bought and sold shares of the company. Torray Investment Partners LLC raised its position in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in Krystal Biotech by 0.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after buying an additional 53 shares during the last quarter. Silvant Capital Management LLC purchased a new position in Krystal Biotech in the 2nd quarter worth about $30,000. HighTower Advisors LLC raised its position in Krystal Biotech by 3.9% in the 2nd quarter. HighTower Advisors LLC now owns 2,129 shares of the company’s stock worth $791,000 after buying an additional 80 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Krystal Biotech by 10.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock worth $366,000 after buying an additional 102 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.